Pricing Log in Create free account
Friday 6 November 2026 Export TXG’s income statement to Excel — free account

10x Genomics

TXG Healthcare Medical Devices

10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.

Revenue
+1.12%
EPS
+31.8%
Free cash flow
−4.61%

Quarter to September 2026, against a year earlier

58.28 0.22 +0.38%
Market cap
$7.6B
P/E
0.0×
Fwd P/E
−95.9×
Dividend yield
—
F-score
6/9
Altman Z
3.99
Beneish M
−3.23
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

10x Genomics (TXG) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, 10x Genomics (TXG) trades at a EV/Sales of 11.5×. Over the past ten years it has ranged from 0.0× (December 2019) to 64.5× (February 2021); the current reading is higher than 64% of that period. That is above the Medical Devices industry median of 2.7× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 2.4× 7.19%
FY2024 2.2× (76.95%)
FY2023 9.7× 38.42%
FY2022 7.0× (78.35%)
FY2021 32.4× (29.24%)
FY2020 45.8× 62.39%
FY2019 28.2× —
FY2018 0.0× —
FY2017 0.0× —

Quarterly newest first

Period EV/Sales Change
Sep 2026 18.2× 152.02%
Jun 2026 7.2× 108.69%
Mar 2026 3.5× 44.55%
Dec 2025 2.4× 51.62%
27 more quarters

Against its own ten years

Low 0.0× High 64.5×
Ten-year median 8.7×
Current reading's percentile 62

EV/Sales against peers

Company EV/Sales
SNN Smith & Nephew SNATS, Inc. compare 1.6×
BRKR Bruker Corporation compare 3.0×
PODD Insulet Corporation compare 3.5×
GMED Globus Medical, Inc. compare 3.5×
BIO Bio-Rad Laboratories, Inc. compare 3.7×
BIO.B Bio-Rad Laboratories, Inc. compare 3.8×
HAE Haemonetics Corporation compare 4.7×
PEN Penumbra, Inc. compare 7.7×
TXG 10x Genomics 11.5×
Medical Devices industry median 2.7×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on TXG